Drug Profile
Research programme: antibacterials and antivirals - Galapagos/GlaxoSmithKline
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Galapagos NV
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Viral infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Bacterial-infections in Belgium
- 04 Nov 2017 No recent reports of development identified for research development in Viral-infections in Belgium
- 09 Feb 2011 Galapagos receives grant from the Innovation by Science and Technology for antivirals development